Demo Data from EDBT 2026 / reviewers in the wild / expert
Ron Bose
dblp:170/9286
· DBLP profile ↗
1ranked-venue papers
0as first author
0since 2021 · last 2015
—ORCID · unresolved
Domains — the database's venue-derived domains; a paper can count in several
Applied, interdisciplinary, general and emerging computing · 1
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
1 paper |
Bioinformatics and computational biology · 100% |
Topics — the 2 heaviest of 2, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Bioinformatics and computational biology › cancer genomics
cancer driver gene identification |
0.2 | 1 | 2015 | Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data · Bioinform. 2015 |
Bioinformatics and computational biology › cancer genomics
somatic mutation analysis |
0.1 | 1 | 2015 | Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data · Bioinform. 2015 |
Methods — techniques the papers use, named apart from their topics
statistical hypothesis testing · 0.2random forest · 0.2patient bias signal · 0.2
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2015 | Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing dataabstractMOTIVATION: Several tools exist to identify cancer driver genes based on somatic mutation data. However, these tools do not account for subclasses of cancer genes: oncogenes, which undergo gain-of-function events, and tumor suppressor genes (TSGs) which undergo loss-of-function. A method which accounts for these subclasses could improve performance while also suggesting a mechanism of action for new putative cancer genes. RESULTS: We develop a panel of five complementary statistical tests and assess their performance against a curated set of 99 HiConf cancer genes using a pan-cancer dataset of 1.7 million mutations. We identify patient bias as a novel signal for cancer gene discovery, and use it to significantly improve detection of oncogenes over existing methods (AUROC = 0.894). Additionally, our test of truncation event rate separates oncogenes and TSGs from one another (AUROC = 0.922). Finally, a random forest integrating the five tests further improves performance and identifies new cancer genes, including CACNG3, HDAC2, HIST1H1E, NXF1, GPS2 and HLA-DRB1. AVAILABILITY AND IMPLEMENTATION: All mutation data, instructions, functions for computing the statistics and integrating them, as well as the HiConf gene panel, are available at www.github.com/Bose-Lab/Improved-Detection-of-Cancer-Genes. CONTACT: [email protected] SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online. Runjun D. Kumar, Adam C. Searleman, Sanjay Joshua Swamidass, Obi L. Griffith, Ron Bose |
Bioinform. | 5 |